Erlotinib belongs to which generation of targeted drugs and indications

Erlotinib is a first-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor and one of the earliest targeted drugs to be marketed. It has a similar mechanism of action to gefitinib, which mainly blocks the growth and division of tumor cells by inhibiting the signaling of the EGFR pathway.第一代靶向药主要对EGFR基因突变阳性的肿瘤有效，尤其在治疗非小细胞肺癌中应用广泛。

The main indication of erlotinib is patients with EGFR gene mutation-positive advanced non-small cell lung cancer (NSCLC), especially lung adenocarcinoma type.它可以作为一线治疗使用，也可用于化疗失败后的后续治疗。 Erlotinib is also approved for the treatment of locally advanced or metastatic pancreatic cancer (in combination with gemcitabine), but this indication is rarely used and is mainly used in the clinical treatment of lung cancer.

Compared with second-generation (such as afatinib) and third-generation (such as osimertinib)EGFR inhibitors, although the safety and efficacy of erlotinib have been widely verified, it has certain limitations in drug resistance. For example, after taking drugs for a period of time, patients often develop drug resistance due to the T790M mutation, and in this case they usually need to be replaced with third-generation targeted drugs. Despite this, erlotinib remains an important initial treatment option for patients with EGFRmutantNSCLC in many countries.

In general, erlotinib, as the first generation EGFR targeted drug, has good effects on patients with positive specific gene mutations, and is still widely used in clinical practice because of its relatively low price and rich clinical experience. Before taking the drug, it is necessary to confirm the suitable population through EGFR gene testing, and monitor the efficacy and possible adverse reactions during the treatment process, such as rash, diarrhea, abnormal liver function, etc.正确的患者筛选与规范的治疗管理，是确保厄洛替尼疗效与安全性的关键。

Reference:https://en.wikipedia.org/wiki/Erlotinib